News

Precision Biologics, Inc. and National Cancer Institute Collaborators Deliver Poster Presentation at the ASCO Annual Meeting June 5, 2022

Strattmont Group2022-06-03T11:11:01-04:00

Precision Biologics, Inc. and our collaborators at the NCI deliver a poster presentation at the...

Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics, San Diego, March 9, 2022

Strattmont Group2022-03-09T10:48:47-05:00

Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics 2022, San...

Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, November 8, 2021, Manchester, UK

Strattmont Group2021-11-05T14:50:15-04:00

Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, Day 1 – November...

Phase II Clinical Trial NEO-201 in Combination with Pembrolizumab Detailed Study Information

Strattmont Group2021-10-28T11:57:03-04:00

The Phase 2 Clinical Trial with a safety lead in, combining Precision Biologics monoclonal antibody...

Precision Biologics to Deliver two Oral Presentations on our Clinical and Scientific Programs at 6th Annual Neoantigen Based Therapies Summit, October 26-28th, Digital Event

Strattmont Group2021-10-28T15:47:15-04:00

Dr Massimo Fantini, Director of Research is Presenting the following Talk entitled : “Stability Tests...

Precision Biologics Commences Phase 2 Clinical Trial using NEO-201 and Pembrolizumab as a 2nd line Therapy in Patients with Solid Tumors

Strattmont Group2021-10-14T11:22:55-04:00

Precision Biologics announces that a Phase 2 Clinical Trial, combining NEO-201 with Pembrolizumab, is recruiting...

Dr. Philip M. Arlen gives scientific presentation at the 4th Annual Europe Neoantigen Summit 20th-22nd April 2021

Strattmont Group2021-04-21T08:30:59-04:00

Dr. Philip M. Arlen gives scientific presentation at the 4th Annual Europe Neoantigen summit, Clinical...